# World Journal of **Diabetes**

World J Diabetes 2024 November 15; 15(11): 2157-2271





Published by Baishideng Publishing Group Inc

W J D World Journal of Diabetes

### Contents

### Monthly Volume 15 Number 11 November 15, 2024

### **EDITORIAL**

2157	Diabetes and obesity: A debate on bariatric interventions and its implications	
	Tatmatsu-Rocha JC, Lima da Silva MR	
2162	Diabetes mellitus and comorbidities in elderly people from the Lugu community: A critical-reflective analysis	
	Tatmatsu-Rocha JC, Gomes-Pinto JC	
2167	Glucagon-like peptide-1 agonists: Role of the gut in hypoglycemia unawareness, and the rationale in type 1 diabetes	
	Mirghani HO	
2173	Targeting neuronal PAS domain protein 2 and KN motif/ankyrin repeat domains 1: Advances in type 2 diabetes therapy	
	Cheng CH, Hao WR, Cheng TH	

Macrophages: Key players in diabetic wound healing 2177 Zhou X, Guo YL, Xu C, Wang J

### **EXPERT CONSENSUS**

2182 Guidelines and consensus: Jejunoileostomy for diabetes mellitus-surgical norms and expert consensus (2023 version)

Shen JW, Ji CY, Fang XD, Yang B, Zhang T, Li ZC, Li HZ, Liu ZY, Tang J, Liao CW, Lu JZ, Yang X, Zhang XG

### **REVIEW**

Autophagy-dependent ferroptosis may play a critical role in early stages of diabetic retinopathy 2189 Sun WJ, An XD, Zhang YH, Tang SS, Sun YT, Kang XM, Jiang LL, Zhao XF, Gao Q, Ji HY, Lian FM

### **ORIGINAL ARTICLE**

### **Basic Study**

2203 Effect of exercise during pregnancy on offspring development through ameliorating high glucose and hypoxia in gestational diabetes mellitus

Tang YB, Wang LS, Wu YH, Zhang LX, Hu LY, Wu Q, Zhou ML, Liang ZX

2220 Tiliroside protects against diabetic nephropathy in streptozotocin-induced diabetes rats by attenuating oxidative stress and inflammation

Shang Y, Yan CY, Li H, Liu N, Zhang HF



### World Journal of Diabetes

### Contents

Monthly Volume 15 Number 11 November 15, 2024

### **LETTER TO THE EDITOR**

- 2237 Role of intestinal glucagon-like peptide-1 in hypoglycemia response impairment in type 1 diabetes Cheng CH, Hao WR, Cheng TH
- 2242 Atrial fibrillation and prediabetes: Interplay between left atrium and systemic diseases Hung MJ
- 2245 Glymphatic system function in diverse glucose metabolism states Byeon H
- 2251 Relationship between age and subfoveal choroidal thickness and its clinical implications Sinha S, Nishant P, Morya AK, Singh A
- 2255 Bariatric and endo-bariatric interventions for diabetes: What is the current evidence? Mondal S, Ambrose Fistus V, Pappachan JM
- Stem cell exosomes: New hope for recovery from diabetic brain hemorrhage 2264 Cheng CH, Hao WR, Cheng TH



### Contents

Monthly Volume 15 Number 11 November 15, 2024

### **ABOUT COVER**

Peer Review of World Journal of Diabetes, Dimiter Avtanski, PhD, Director, Endocrine Research Laboratory, Friedman Diabetes Institute, Lenox Hill Hospital, New York, NY 10022, United States. davtanski@northwell.edu

### **AIMS AND SCOPE**

The primary aim of World Journal of Diabetes (WJD, World J Diabetes) is to provide scholars and readers from various fields of diabetes with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WID mainly publishes articles reporting research results and findings obtained in the field of diabetes and covering a wide range of topics including risk factors for diabetes, diabetes complications, experimental diabetes mellitus, type 1 diabetes mellitus, type 2 diabetes mellitus, gestational diabetes, diabetic angiopathies, diabetic cardiomyopathies, diabetic coma, diabetic ketoacidosis, diabetic nephropathies, diabetic neuropathies, Donohue syndrome, fetal macrosomia, and prediabetic state.

### **INDEXING/ABSTRACTING**

The WID is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Current Contents/Clinical Medicine, Journal Citation Reports/Science Edition, PubMed, PubMed Central, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2024 Edition of Journal Citation Reports® cites the 2023 journal impact factor (JIF) for WJD as 4.2; JIF without journal self cites: 4.1; 5-year JIF: 4.2; JIF Rank: 40/186 in endocrinology and metabolism; JIF Quartile: Q1; and 5year JIF Quartile: Q2.

### **RESPONSIBLE EDITORS FOR THIS ISSUE**

Production Editor: Yu-Xi Chen; Production Department Director: Xu Guo; Cover Editor: Jia-Ru Fan.

NAME OF JOURNAL World Journal of Diabetes	INSTRUCTIONS TO AUTHORS https://www.wjgnet.com/bpg/gerinfo/204
<b>ISSN</b> ISSN 1948-9358 (online)	GUIDELINES FOR ETHICS DOCUMENTS https://www.wjgnet.com/bpg/GerInfo/287
LAUNCH DATE	GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
FREQUENCY	PUBLICATION ETHICS
EDITORS-IN-CHIEF	PUBLICATION MISCONDUCT
Lu Cai, Md. Shahidul Islam, Michael Horowitz EDITORIAL BOARD MEMBERS	https://www.wjgnet.com/bpg/gerinfo/208 ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/1948-9358/editorialboard.htm	https://www.wjgnet.com/bpg/gerinfo/242
November 15, 2024	https://www.wjgnet.com/bpg/GerInfo/239
COPYRIGHT © 2024 Baishideng Publishing Group Inc	ONLINE SUBMISSION https://www.f6publishing.com

© 2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA E-mail: office@baishideng.com https://www.wjgnet.com



WJD

# World Journal of Diabetes

Submit a Manuscript: https://www.f6publishing.com

World J Diabetes 2024 November 15; 15(11): 2173-2176

DOI: 10.4239/wjd.v15.i11.2173

ISSN 1948-9358 (online)

EDITORIAL

# Targeting neuronal PAS domain protein 2 and KN motif/ankyrin repeat domains 1: Advances in type 2 diabetes therapy

Chun-Han Cheng, Wen-Rui Hao, Tzu-Hurng Cheng

Specialty type: Endocrinology and metabolism

Provenance and peer review: Invited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's classification Scientific Quality: Grade B, Grade B, Grade B, Grade C Novelty: Grade B, Grade B Creativity or Innovation: Grade B, Grade B Scientific Significance: Grade A, Grade A

P-Reviewer: Balbaa ME; Horowitz M; Wu QN

Received: July 21, 2024 Revised: August 21, 2024 Accepted: September 13, 2024 Published online: November 15, 2024 Processing time: 86 Days and 22.3 Hours



Chun-Han Cheng, Department of Medical Education, Linkou Chang Gung Memorial Hospital, Taoyuan 33305, Taiwan

Wen-Rui Hao, Division of Cardiology, Department of Internal Medicine, Shuang Ho Hospital, Ministry of Health and Welfare, Taipei Medical University, New Taipei 23561, Taiwan

Wen-Rui Hao, Division of Cardiology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11002, Taiwan

Tzu-Hurng Cheng, Department of Biochemistry, School of Medicine, College of Medicine, China Medical University, Taichung 404328, Taiwan

Co-first authors: Chun-Han Cheng and Wen-Rui Hao.

Corresponding author: Tzu-Hurng Cheng, PhD, Professor, Department of Biochemistry, School of Medicine, College of Medicine, China Medical University, No. 91 Xueshi Road, North District, Taichung 404328, Taiwan. thcheng@mail.cmu.edu.tw

### Abstract

This editorial summarizes the latest literature on the roles of neuronal PAS domain protein 2 and KN motif/ankyrin repeat domain 1 in type 2 diabetes (T2D). We highlight their involvement in  $\beta$ -cell dysfunction, explore their potential as therapeutic targets, and discuss the implications for new treatment strategies. We offer valuable insights into relevant gene regulation and cellular mechanisms relevant for the targeted management of T2D.

Key Words: Type 2 diabetes; Neuronal PAS domain protein 2; KN motif and ankyrin repeat domain 1; β-cell dysfunction; Therapeutic target

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: This editorial explores the pivotal roles of NPAS2 and KANK1 in type 2 diabetes (T2D). It elucidates their contribution to  $\beta$ -cell dysfunction, highlighting their potential for targeted therapies. Insights from this editorial may guide the development of innovative treatment approaches against T2D.



WJD | https://www.wjgnet.com

Citation: Cheng CH, Hao WR, Cheng TH. Targeting neuronal PAS domain protein 2 and KN motif/ankyrin repeat domains 1: Advances in type 2 diabetes therapy. World J Diabetes 2024; 15(11): 2173-2176 URL: https://www.wjgnet.com/1948-9358/full/v15/i11/2173.htm DOI: https://dx.doi.org/10.4239/wjd.v15.i11.2173

### INTRODUCTION

The ongoing fight against type 2 diabetes (T2D) has recently gained momentum with discoveries about the genetic and molecular underpinnings of this widespread disease. A pivotal study by Yin et al[1] in the World Journal of Diabetes has highlighted the significance of the transcription factor NPAS2 (neuronal PAS domain protein 2) and its downstream target KANK1 (KN motif and ankyrin repeat domain 1) in the dysfunction of pancreatic  $\beta$ -cells, a key event in the development of T2D. Since  $\beta$ -cell dysfunction is central to T2D pathogenesis, a deeper understanding of these regulatory mechanisms is crucial for advancing therapeutic approaches. NPAS2 is a component of the circadian clock system, influencing various physiological processes, including glucose metabolism[2]. Its role in  $\beta$ -cell function and insulin secretion has opened new avenues for diabetes research. The study by Yin et al. demonstrates how NPAS2 modulates KANK1 expression, thereby affecting the structural and functional integrity of  $\beta$ -cells. KANK1 is crucial for maintaining cell adhesion and cytoskeletal dynamics, both essential for  $\beta$ -cell function[3]. The interaction between KANK1 and focal adhesion proteins influences the stability and organization of microtubules and actin filaments, thereby affecting insulin secretion[4]. Changes in KANK1 expression can disrupt these processes, causing  $\beta$ -cell malfunction and accelerating T2D development. This editorial contextualizes these findings within the broader scope of T2D research. By exploring the complex pathways involving NPAS2 and KANK1, we can better understand their implications for new T2D therapies. The study by Yin *et al*[1] underscores the need for probing these molecular pathways to preserve  $\beta$ -cell function and improve T2D outcomes.

### ROLE OF NPAS2 IN $\beta$ -CELL DYSFUNCTION

Yin *et al*[1] highlighted the vital role of NPAS2 in the dysfunction of  $\beta$ -cells in T2D. The expression of NPAS2 was upregulated in the islet  $\beta$ -cells of mice with T2D. Upregulation of *NPAS2* regulated the expression of *KANK1*, a gene essential for cellular structure and function. Yin et al[1] demonstrated that NPAS2 overexpression was correlated with elevated KANK1 levels, contributing to β-cell apoptosis and impaired insulin secretion. These findings suggest that NPAS2 is a central regulator of  $\beta$ -cell health, and its dysregulation can drive the progression of T2D[1]. KANK1 is involved in several cellular processes, including protein binding, mechanical force sensing, and phase separation, that are crucial for maintaining cellular integrity and function[3]. Specifically, KANK1 shapes focal adhesions, which are essential for cell signaling and structural support[4]. In addition, these adhesions are integral to  $\beta$ -cell function because they form "secreting adhesions," which are essential for insulin secretion[5]. The interactions between KANK1 and other cellular components, such as cortical complexes regulating insulin secretion, underscore its importance in maintaining the functionality of  $\beta$ -cells[6]. Dysregulation of these interactions due to NPAS2 overexpression disrupts the delicate balance needed for effective insulin secretion, thus promoting  $\beta$ -cell dysfunction in T2D. The findings of Yin *et al*[1] are supported by structural studies on KANK1, which revealed its role in coordinating the actin and microtubule cytoskeletons at focal adhesions; this coordination is crucial for maintaining cellular architecture and function[7]. Disruptions in these structures due to NPAS2-induced overexpression of KANK1 lead to cellular dysfunction, facilitating the development of T2D. In summary, NPAS2 serves as a major regulator of  $\beta$ -cell health by modulating *KANK1* expression. The upregulation of NPAS2 expression in T2D upregulates the expression of KANK1, disrupting cellular architecture and function and thus causing  $\beta$ -cell apoptosis and impaired insulin secretion. These insights deepen our understanding of the molecular mechanisms underlying  $\beta$ -cell dysfunction in T2D and highlight the potential of NPAS2 and KANK1 as therapeutic targets against T2D progression.

### KANK1 AS A DOWNSTREAM EFFECTOR

KANK1, a downstream target of NPAS2, contributes to β-cell dysfunction in T2D (Figure 1). Evidence suggests a significant correlation between NPAS2 expression and KANK1 expression in T2D, highlighting a potential pathway for therapeutic intervention[1]. Specifically, KANK1 regulates cellular adhesion and structure, which are essential for maintaining  $\beta$ -cell function and insulin secretion[3]. Knocking down NPAS2 and KANK1 in cell models increased the proliferation of  $\beta$ -cells, implying that downregulating the expression of these genes can help preserve the function of  $\beta$ cells in patients with T2D[4,5]. Therefore, the NPAS2-KANK1 pathway may be targeted to treat T2D by enhancing  $\beta$ -cell survival and function. KANK1 is essential for structural interactions occurring at focal adhesions; it coordinates the actin and microtubule cytoskeletons, which are vital for  $\beta$ -cell adhesion and insulin secretion[6,8]. These findings highlight the importance of KANK1 in  $\beta$ -cell physiology and underscore its potential as a therapeutic target in T2D management. The ability of KANK1 to influence cellular structures further emphasizes its role in the pathophysiology of T2D and its potential for use in T2D therapies aimed at modulating the expression or function of this protein[7,9].





Figure 1 Roles of NPAS2 and KANK1 in  $\beta$ -cell dysfunction in type 2 diabetes. Figure depicts the key roles of NPAS2 and KANK1 in the dysfunction of pancreatic  $\beta$ -cells, a key event in the development of type 2 diabetes (T2D). The expression of NPAS2, a transcription factor, is upregulated in the islet  $\beta$ -cells of patients with T2D, leading to the upregulation of *KANK1* expression. KANK1 disrupts the structural and functional integrity of  $\beta$ -cells by impairing cell adhesion and cytoskeletal dynamics. The interaction between NPAS2 and KANK1 contributes to  $\beta$ -cell apoptosis and impaired insulin secretion, thereby promoting the progression of T2D. This pathway highlights NPAS2 and KANK1 as potential therapeutic targets for preserving  $\beta$ -cell function and improving diabetes management.

### **IMPLICATIONS FOR T2D THERAPY**

The discovery of the NPAS2-KANK1 pathway mediating  $\beta$ -cell dysfunction has opened promising new avenues for therapeutic interventions against T2D. Novel T2D therapies can be developed by targeting the molecular mechanisms involving NPAS2 and KANK1 to preserve β-cell function and enhance insulin secretion-factors crucial to managing glycemic control. Yin *et al*[1] highlighted the feasibility of this approach by demonstrating that knocking down NPAS2 and *KANK1* in cell models increased  $\beta$ -cell proliferation-a viable strategy for combating  $\beta$ -cell dysfunction[1]. KANK1 plays a key structural role in coordinating the actin and microtubule cytoskeletons at focal adhesions; this role is essential for maintaining cell integrity and function [3,4]. The aforementioned coordination is crucial for  $\beta$ -cell function because it helps sustain the structural and mechanical properties necessary for insulin secretion. The interplay between cytoskeletal elements and focal adhesions, as described by Guo et al[3], highlights the feasibility of targeting these interactions to improve the resilience and functionality of  $\beta$ -cells. Notably, surgical interventions such as Roux-en-Y gastric bypass surgery have been demonstrated to downregulate the expression of NPAS2 and KANK1; therefore, surgical approaches may be explored to manage T2D by modulating the NPAS2-KANK1 pathway[1]. Pharmacological and surgical interventions may be combined to preserve  $\beta$ -cell health and improve T2D outcomes. The role of the NPAS2-KANK1 pathway in mediating the function of  $\beta$ -cells emphasizes its significance in the pathophysiology of T2D. Targeting this pathway through pharmacological or surgical approaches can optimize therapeutic outcomes by improving  $\beta$ -cell viability and insulin secretion. Future treatments may harness these insights to optimize glycemic control and overall care for patients with T2D.

Raisbideng® WJD | https://www.wjgnet.com

November 15, 2024 Volume 15 Issue 11

### CONCLUSION

Yin *et al*[1] clarified the critical molecular pathways underlying T2D by highlighting the roles of NPAS2 and KANK1 in  $\beta$ cell dysfunction. The NPAS2-KANK1 pathway may serve as a promising therapeutic target for preserving  $\beta$ -cell function to optimize T2D management. Targeting this pathway can help maintain insulin secretion and glycemic control in patients with T2D. Understanding the structural and functional dynamics of KANK1 at focal adhesions can help researchers devise strategies for protecting  $\beta$ -cells from dysfunction[3,4]. The interaction between talin and KANK1 is essential for coordinating the actin and microtubule cytoskeletons at focal adhesions; this coordination is crucial for  $\beta$ -cell viability and insulin secretion [4,7]. These molecular connections should be leveraged to develop new therapeutic strategies aimed at enhancing the resilience of  $\beta$ -cells. Future studies should explore relevant genetic and molecular interactions, investigating how they can be modified to devise precise and effective therapies for T2D. Knowledge about the NPAS2-KANK1 pathway and its broader implications may guide the development of novel therapies for improving the quality of life of patients with T2D. Targeting this pathway can help preserve  $\beta$ -cell function and thus optimize T2D management[5,6].

### FOOTNOTES

Author contributions: Cheng TH as a co-corresponding author, played a key role in overseeing the revision process, providing critical feedback, and ensuring the editorial's accuracy and coherence; Cheng CH and Hao WR have made substantial contributions, and their equal roles in the preparation of the manuscript are acknowledged. All authors have reviewed and approved the final version of the editorial. Cheng CH and Hao WR are co-first authors and have contributed equally to drafting the Editorial. Their contributions include the initial writing, literature review, and conceptualization of the editorial content.

Conflict-of-interest statement: All authors declare having no conflicts of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country of origin: Taiwan

ORCID number: Tzu-Hurng Cheng 0000-0002-9155-4169.

S-Editor: Ou XL L-Editor: A P-Editor: Chen YX

### REFERENCES

- Yin YB, Ji W, Liu YL, Gao QH, He DD, Xu SL, Fan JX, Zhang LH. cNPAS2 induced β cell dysfunction by regulating KANK1 expression in 1 type 2 diabetes. World Journal of Diabetes 2024; 15: 1932-1941 [DOI: 10.4239/wjd.v15.i9.1932]
- 2 Karuga FF, Jaromirska J, Sochal M, Białasiewicz P, Gabryelska A. Association between glucose metabolism, the circadian cycle and hypoxia: Evaluation of the NPAS2 and Rev-Erb-α protein serum levels in obstructive sleep apnea patients - a pilot study. Dent Med Probl 2024; 61: 465-469 [PMID: 38804230 DOI: 10.17219/dmp/185718]
- Guo K, Zhang J, Huang P, Xu Y, Pan W, Li K, Chen L, Luo L, Yu W, Chen S, He S, Wei Z, Yu C. KANK1 shapes focal adhesions by 3 orchestrating protein binding, mechanical force sensing, and phase separation. Cell Rep 2023; 42: 113321 [PMID: 37874676 DOI: 10.1016/j.celrep.2023.113321]
- 4 Li X, Goult BT, Ballestrem C, Zacharchenko T. The structural basis of the talin-KANK1 interaction that coordinates the actin and microtubule cytoskeletons at focal adhesions. Open Biol 2023; 13: 230058 [PMID: 37339751 DOI: 10.1098/rsob.230058]
- Fye MA, Kaverina I. Insulin secretion hot spots in pancreatic β cells as secreting adhesions. Front Cell Dev Biol 2023; 11: 1211482 [PMID: 5 37305687 DOI: 10.3389/fcell.2023.1211482]
- Noordstra I, van den Berg CM, Boot FWJ, Katrukha EA, Yu KL, Tas RP, Portegies S, Viergever BJ, de Graaff E, Hoogenraad CC, de Koning 6 EJP, Carlotti F, Kapitein LC, Akhmanova A. Organization and dynamics of the cortical complexes controlling insulin secretion in β-cells. J Cell Sci 2022; 135 [PMID: 35006275 DOI: 10.1242/jcs.259430]
- Bouchet BP, Gough RE, Ammon YC, van de Willige D, Post H, Jacquemet G, Altelaar AM, Heck AJ, Goult BT, Akhmanova A. Talin-7 KANK1 interaction controls the recruitment of cortical microtubule stabilizing complexes to focal adhesions. Elife 2016; 5 [PMID: 27410476 DOI: 10.7554/eLife.18124]
- Pan W, Sun K, Tang K, Xiao Q, Ma C, Yu C, Wei Z. Structural insights into ankyrin repeat-mediated recognition of the kinesin motor protein 8 KIF21A by KANK1, a scaffold protein in focal adhesion. J Biol Chem 2018; 293: 1944-1956 [PMID: 29217769 DOI: 10.1074/jbc.M117.815779]
- 9 Stubb A, Guzmán C, Närvä E, Aaron J, Chew TL, Saari M, Miihkinen M, Jacquemet G, Ivaska J. Superresolution architecture of cornerstone focal adhesions in human pluripotent stem cells. Nat Commun 2019; 10: 4756 [PMID: 31628312 DOI: 10.1038/s41467-019-12611-w]



WJD | https://www.wjgnet.com



## Published by Baishideng Publishing Group Inc 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA Telephone: +1-925-3991568 E-mail: office@baishideng.com Help Desk: https://www.f6publishing.com/helpdesk https://www.wjgnet.com

